Australian Clinical Labs Limited

ASX:ACL Stock Report

Market Cap: AU$356.4m

Australian Clinical Labs Management

Management criteria checks 1/4

Australian Clinical Labs' CEO is Melinda McGrath, appointed in Dec 2020, has a tenure of 5.42 years. total yearly compensation is A$3.92M, comprised of 37.5% salary and 62.5% bonuses, including company stock and options. directly owns 1.97% of the company’s shares, worth A$6.85M. The average tenure of the management team and the board of directors is 8.3 years and 2.8 years respectively.

Key information

Melinda McGrath

Chief executive officer

AU$3.9m

Total compensation

CEO salary percentage37.54%
CEO tenure5.4yrs
CEO ownership2.0%
Management average tenure8.3yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Narrative Update • May 05

ACL: Index Inclusion And Franked Dividend Will Support Undervalued Share Price

Analysts have trimmed their price target for Australian Clinical Labs slightly to A$3.48 from A$3.50, reflecting updated assumptions around revenue growth, profit margins, the discount rate and future P/E multiples. What's in the News Australian Clinical Labs has been added to the S&P/ASX Emerging Companies Index, placing the stock in a broader benchmark followed by many Australian equity investors (Key Developments).
Narrative Update • Apr 20

ACL: Index Inclusion And Dividend Policy Will Support Future Share Price Upside

Analysts have reduced their price target for Australian Clinical Labs to A$2.58 from A$3.37, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Australian Clinical Labs Limited has been added to the S&P/ASX Emerging Companies Index, reflecting its inclusion in this benchmark group of smaller listed companies (Key Developments).
Narrative Update • Apr 05

ACL: Index Inclusion And Dividend Settings Will Shape A Balanced Outlook

Analysts have trimmed their price target on Australian Clinical Labs to A$2.20 from A$2.40, citing slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, partly offset by adjusted profit margin expectations. What's in the News Australian Clinical Labs Limited (ASX:ACL) is being added to the S&P/ASX Emerging Companies Index, which can increase visibility among index and fund investors (Index Constituent Adds).
Narrative Update • Mar 22

ACL: Future Dividend Visibility Will Support Confidence In Undervalued Share Price

Analysts have trimmed their price target on Australian Clinical Labs from A$3.85 to A$3.50, citing updated assumptions that include a higher discount rate, a lower revenue growth outlook, a slightly higher profit margin and a modestly reduced future P/E multiple. What's in the News The Board has declared a fully franked interim dividend of A$0.0375 per share for the six months ending 31 December 2025, providing clearer visibility on near term cash returns (Key Developments).
Narrative Update • Mar 07

ACL: Dividend Timeline And Updated Assumptions Will Shape A Measured Outlook

Analysts have nudged their price target for Australian Clinical Labs higher to A$2.40, reflecting updated assumptions around revenue growth, profit margins, the discount rate and future P/E that slightly increase their view of fair value from A$2.30. What's in the News The board has declared a fully franked interim dividend of A$0.0375 per share for the six months ending 31 December 2025, indicating a cash return to shareholders for that period (Key Developments).
Narrative Update • Feb 21

ACL: Dividend Timeline And Revised Assumptions Will Guide A Balanced Outlook

Analysts have reduced their price target on Australian Clinical Labs by A$0.50 to A$2.30, citing updated assumptions around revenue growth, profit margin, discount rate and future P/E multiples. What's in the News The board has declared a fully franked interim dividend of A$0.0375 per share for the six months ending 31 December 2025 (Key Developments).
Narrative Update • Feb 07

ACL: Updated Assumptions Will Support Confidence In Undervalued Share Price

Analysts have revised their price target on Australian Clinical Labs to A$3.85. The update reflects slightly adjusted assumptions around discount rate, revenue growth, profit margin and future P/E, while keeping fair value unchanged at A$3.85.
Narrative Update • Jan 24

ACL: Updated Discount Rate And Margins Will Shape A Measured Outlook

Analysts have trimmed their price target for Australian Clinical Labs to A$2.80 from A$2.90, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together point to a slightly more cautious valuation outlook. Valuation Changes Fair Value Estimate: Trimmed slightly from A$2.90 to A$2.80, reflecting a modestly lower central valuation point.
Narrative Update • Jan 09

ACL: Share Buyback Plan Will Support Future Share Price Upside

Analysts have trimmed their price target for Australian Clinical Labs to about A$3.37 from A$3.40, citing slightly softer assumptions for revenue growth and profit margins, while keeping the assumed future P/E multiple broadly unchanged. What's in the News The Board of Directors authorized a share buyback plan on October 23, 2025, signaling an intention to return capital to shareholders over time (Key Developments).
Narrative Update • Dec 15

ACL: Share Buyback And Cyber Penalty Resolution Will Support Stronger Outlook

Narrative Update on Australian Clinical Labs Analysts have trimmed their price target on Australian Clinical Labs from approximately A$4.73 to around A$3.85. This reflects slightly higher perceived risk, more moderate valuation multiples, and only modest upgrades to long term growth and margin assumptions.
Narrative Update • Nov 30

ACL: Share Buyback Program Will Drive Shareholder Value Over The Next Year

Analysts have reaffirmed their price target for Australian Clinical Labs at $3.40, citing stable financial forecasts and consistent assumptions for discount rate, revenue growth, profit margin, and future price-earnings ratio. What's in the News The Board of Directors authorized a buyback plan on October 23, 2025 (Key Developments).
Narrative Update • Nov 16

ACL: Share Buyback Plan And Acquisitions Will Drive Future Upside

Analysts have maintained their price target for Australian Clinical Labs at $3.40. They cite steady expectations for profit margins and revenue growth, even with a slight increase in the discount rate.
Narrative Update • Nov 02

ACL: Share Buyback And Acquisition Plans Will Drive Strong Shareholder Returns

Analysts have revised their price target for Australian Clinical Labs slightly downward to $3.40. This adjustment is due to marginally lower expectations for revenue growth and future earnings multiples.
Narrative Update • Oct 18

AI And Laboratory Automation Will Advance Personalized Testing

Analysts have lowered their price target for Australian Clinical Labs from $3.60 to $3.40. They cite adjustments to their revenue growth forecasts and a slightly higher discount rate in their valuation model.
Analysis Article • Mar 02

Australian Clinical Labs Limited Just Missed Earnings - But Analysts Have Updated Their Models

It's been a mediocre week for Australian Clinical Labs Limited ( ASX:ACL ) shareholders, with the stock dropping 16% to...
User avatar
New Narrative • Feb 09

Operational Improvements And New Genomic Tests Aim To Improve Future Outlook

Improving collection centers and digital transformations are set to enhance operational efficiency, boosting profit margins and supporting revenue growth.
Analysis Article • Sep 03

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Australian Clinical Labs Limited ( ASX:ACL ) shares have continued their recent momentum with a 29% gain in the last...
Analysis Article • Sep 02

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Australian Clinical Labs Limited ( ASX:ACL ), might not be a large cap stock, but it led the ASX gainers with a...
Analysis Article • Jun 20

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Feb 21

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Key Insights The projected fair value for Australian Clinical Labs is AU$5.01 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Dec 08

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

While Australian Clinical Labs Limited ( ASX:ACL ) might not be the most widely known stock at the moment, it saw a...
Analysis Article • Aug 14

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article • Feb 25

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited ( ASX:ACL ) last week reported its latest half-yearly results, which makes it a good...
Analysis Article • Dec 22

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Celebrations may be in order for Australian Clinical Labs Limited ( ASX:ACL ) shareholders, with the analysts...
Analysis Article • Dec 21

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Australian Clinical Labs Limited ( ASX:ACL ) shareholders would be excited to see that the share price has had a great...
Analysis Article • Sep 01

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Australian Clinical Labs Limited ( ASX:ACL ) just reported healthy earnings but the stock price didn't move much. Our...

CEO Compensation Analysis

How has Melinda McGrath's remuneration changed compared to Australian Clinical Labs's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

AU$26m

Sep 30 2025n/an/a

AU$29m

Jun 30 2025AU$4mAU$1m

AU$32m

Mar 31 2025n/an/a

AU$32m

Dec 31 2024n/an/a

AU$31m

Sep 30 2024n/an/a

AU$27m

Jun 30 2024AU$2mAU$873k

AU$24m

Mar 31 2024n/an/a

AU$20m

Dec 31 2023n/an/a

AU$15m

Sep 30 2023n/an/a

AU$26m

Jun 30 2023AU$1mAU$873k

AU$36m

Mar 31 2023n/an/a

AU$55m

Dec 31 2022n/an/a

AU$73m

Sep 30 2022n/an/a

AU$126m

Jun 30 2022AU$2mAU$873k

AU$178m

Mar 31 2022n/an/a

AU$156m

Dec 31 2021n/an/a

AU$134m

Sep 30 2021n/an/a

AU$97m

Jun 30 2021AU$2mAU$875k

AU$60m

Mar 31 2021n/an/a

AU$79m

Dec 31 2020n/an/a

AU$98m

Sep 30 2020n/an/a

AU$70m

Jun 30 2020AU$2mAU$852k

AU$41m

Compensation vs Market: Melinda's total compensation ($USD2.84M) is above average for companies of similar size in the Australian market ($USD621.66K).

Compensation vs Earnings: Melinda's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Melinda McGrath

5.4yrs
Tenure
AU$3,915,944
Compensation

Ms. Melinda McGrath is Chief Executive Officer and Executive Director at Australian Clinical Labs Limited since December 19, 2020 and serves as its Managing Director. She served as Chief Executive Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Melinda McGrath
CEO, MD & Executive Director5.4yrsAU$3.92m1.97%
A$ 7.0m
Matthew Cordingley
Chief Financial Officer1.3yrsAU$772.06kno data
Anthony Friedli
Chief Operating Officer10.3yrsno data0.40%
A$ 1.4m
Sean Jackson
Chief Information Officer11.3yrsno datano data
Joe Geran
National Marketing Directorno datano datano data
Tony Landgren
National Medical Director & Chief Pathologist17.3yrsno datano data
Chris Brownlow
Chief Executive Officer of New South Wales & Australian Capital Territory15.3yrsno datano data
Shae Seymour
Chief Risk Officer & CEO of WA/SA/NT8.3yrsno datano data
Eleanor Padman
Company Secretary5.1yrsno datano data
Darren McKee
Chief Executive Officer of Victoria3.3yrsAU$37.27kno data
8.3yrs
Average Tenure

Experienced Management: ACL's management team is seasoned and experienced (8.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Melinda McGrath
CEO, MD & Executive Director5.4yrsAU$3.92m1.97%
A$ 7.0m
Christine Bartlett
Independent Non-Executive Director2.8yrsAU$144.59k0.011%
A$ 38.2k
Stephen Roche
Independent Chairmanless than a yearAU$3.26k0.037%
A$ 133.6k
Mark Haberlin
Independent Non-Executive Director5.1yrsAU$146.32k0.025%
A$ 90.7k
Sarah Butler
Independent Non-Executive Director1.3yrsAU$52.98k0.012%
A$ 43.2k
2.8yrs
Average Tenure

Experienced Board: ACL's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/13 15:08
End of Day Share Price 2026/05/13 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Australian Clinical Labs Limited is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lyanne HarrisonBofA Global Research
Shane StoreyCanaccord Genuity
Citi ResearchCitigroup Inc